Case Rep Ophthalmol: 人工晶状体的off-label使用与“背驮式”技术

2019-01-16 MedSci MedSci原创

纽约大学医学院的Schempf T和华盛顿大学眼科学系的Jung HC两人,近日在Case Rep Ophthalmol杂志上发表了一篇重要的研究论文,他们报告了一例高度近视的假性晶状体病患者,他通过"背负式"技术进行人工晶状体(pIOL)体外放置,这样也允许在他的另一眼中放置人工晶状体(IOL),从而改善视力的敏锐程度。

纽约大学医学院的Schempf T和华盛顿大学眼科学系的Jung HC两人,近日在Case Rep Ophthalmol杂志上发表了一篇重要的研究论文,他们报告了一例高度近视的假性晶状体病患者,他通过"背负式"技术进行人工晶状体(pIOL)体外放置,这样也允许在他的另一眼中放置人工晶状体(IOL),从而改善视力的敏锐程度。

这是一名患有左眼IOL植入物的66岁高度近视的假性男性患者,该男性因为有晶状体,所以选择右眼进行手术。鉴于双眼的严重近视状态,他接受了后置pIOL,采用背驮式技术治疗假性左眼,随后进行了标准的白内障手术和右眼人工晶状体植入手术。对于左眼,未矫正的最佳视力从20/70提高到20/25。

因此,这个案例证明了,使用背负技术可以在假性高度近视患者中成功对有晶体的眼睛进行人工晶状体移植,从而提高了视力,并最终允许将IOL置于对侧眼中。这种标签外使用pIOL的技术,可以为眼科医生提供一种具有严重屈光不正的假晶状体的替代选择。

原文出处:

Schempf, T. and H.C. Jung, Off-Label Use of Phakic Intraocular Lens with a "Piggyback" Technique. Case Rep Ophthalmol, 2018. 9(3): p. 465-472.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1946328, encodeId=7a7f1946328d2, content=<a href='/topic/show?id=6aad2480499' target=_blank style='color:#2F92EE;'>#人工晶状体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24804, encryptionId=6aad2480499, topicName=人工晶状体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Nov 06 21:30:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057503, encodeId=8d10205e503e7, content=<a href='/topic/show?id=df691326e17' target=_blank style='color:#2F92EE;'>#off-label#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13267, encryptionId=df691326e17, topicName=off-label)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Thu Nov 21 08:30:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027954, encodeId=a613202e9548d, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 10 12:30:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541425, encodeId=8b9f1541425ef, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Jan 18 12:30:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624908, encodeId=8f64162490862, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Fri Jan 18 12:30:00 CST 2019, time=2019-01-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1946328, encodeId=7a7f1946328d2, content=<a href='/topic/show?id=6aad2480499' target=_blank style='color:#2F92EE;'>#人工晶状体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24804, encryptionId=6aad2480499, topicName=人工晶状体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Nov 06 21:30:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057503, encodeId=8d10205e503e7, content=<a href='/topic/show?id=df691326e17' target=_blank style='color:#2F92EE;'>#off-label#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13267, encryptionId=df691326e17, topicName=off-label)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Thu Nov 21 08:30:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027954, encodeId=a613202e9548d, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 10 12:30:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541425, encodeId=8b9f1541425ef, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Jan 18 12:30:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624908, encodeId=8f64162490862, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Fri Jan 18 12:30:00 CST 2019, time=2019-01-18, status=1, ipAttribution=)]
    2019-11-21 zz70
  3. [GetPortalCommentsPageByObjectIdResponse(id=1946328, encodeId=7a7f1946328d2, content=<a href='/topic/show?id=6aad2480499' target=_blank style='color:#2F92EE;'>#人工晶状体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24804, encryptionId=6aad2480499, topicName=人工晶状体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Nov 06 21:30:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057503, encodeId=8d10205e503e7, content=<a href='/topic/show?id=df691326e17' target=_blank style='color:#2F92EE;'>#off-label#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13267, encryptionId=df691326e17, topicName=off-label)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Thu Nov 21 08:30:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027954, encodeId=a613202e9548d, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 10 12:30:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541425, encodeId=8b9f1541425ef, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Jan 18 12:30:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624908, encodeId=8f64162490862, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Fri Jan 18 12:30:00 CST 2019, time=2019-01-18, status=1, ipAttribution=)]
    2019-03-10 仁医06
  4. [GetPortalCommentsPageByObjectIdResponse(id=1946328, encodeId=7a7f1946328d2, content=<a href='/topic/show?id=6aad2480499' target=_blank style='color:#2F92EE;'>#人工晶状体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24804, encryptionId=6aad2480499, topicName=人工晶状体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Nov 06 21:30:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057503, encodeId=8d10205e503e7, content=<a href='/topic/show?id=df691326e17' target=_blank style='color:#2F92EE;'>#off-label#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13267, encryptionId=df691326e17, topicName=off-label)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Thu Nov 21 08:30:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027954, encodeId=a613202e9548d, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 10 12:30:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541425, encodeId=8b9f1541425ef, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Jan 18 12:30:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624908, encodeId=8f64162490862, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Fri Jan 18 12:30:00 CST 2019, time=2019-01-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1946328, encodeId=7a7f1946328d2, content=<a href='/topic/show?id=6aad2480499' target=_blank style='color:#2F92EE;'>#人工晶状体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24804, encryptionId=6aad2480499, topicName=人工晶状体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Nov 06 21:30:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057503, encodeId=8d10205e503e7, content=<a href='/topic/show?id=df691326e17' target=_blank style='color:#2F92EE;'>#off-label#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13267, encryptionId=df691326e17, topicName=off-label)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Thu Nov 21 08:30:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027954, encodeId=a613202e9548d, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 10 12:30:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541425, encodeId=8b9f1541425ef, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Jan 18 12:30:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624908, encodeId=8f64162490862, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Fri Jan 18 12:30:00 CST 2019, time=2019-01-18, status=1, ipAttribution=)]
    2019-01-18 yaanren

相关资讯

J Cataract Refract Surg:飞秒激光调节人工晶状体的功率:体外评估蓝光滤光片中的功率变化、调制传递函数、光透射和光散射

来自犹他州盐湖城犹他大学眼科中心的Nguyen J近日在J Cataract Refract Surg发表了一项工作,他们对飞秒激光器调整功率之前和之后蓝光滤光IOL的人工晶状体(IOL)功率、调制传递系数(MTF)、光透射和光散射等情况进行了研究。

Eye Contact Lens: 隐形眼镜磨损对人工晶状体计算生物测量的影响!

杜克大学医学院眼科系的Meyer JJ近日在Eye Contact Lens杂志上发表了他们近期的一项工作,他们研究了隐形眼镜(CL)磨损对白内障手术的生物学参数的影响,以及隐形眼镜(CL)裂缝是否可以减少人工晶状体(IOL)的预测误差。

J Cataract Refract Surg:考虑后部角膜散光的复杂曲面人工晶状体屈光计算新算法

加利福尼亚州圣安娜的雅培医疗光学公司和美国得克萨斯州休斯顿贝勒医学院卡伦眼科研究所(Koch)以及加拿大多伦多大学眼科与视觉科学系的Canovas C近日在J Cataract Refract Surg报告了一项工作,他们研究了包含后角膜散光(PCA)效应在内的新算法,新算法可以提高对复杂曲面的人工晶状体(IOL)功率计算的准确性。

药物根治白内障?不可行,手术时机和人工晶状体选择有门道

白内障是每个人都可能要面临的问题。如果说一个老年人能够生存到正常自然寿命,绝大多数会有白内障。这是像我们长白头发一样的自然老化过程。“70岁以上人群中,白内障患者约占到一半。”复旦大学附属眼耳鼻喉科医院眼科主任卢奕教授告诉我们,“需要注意的是,现在尚无逆转白内障的眼药水或其他药物,目前唯一有效的治疗方法就是手术。当然,在视力受到严重损害之前,框架眼镜或接触镜可能会暂时提高患者的视力。”镜头模糊了“

Clin Ophthalmol:相同材料的复曲面与非复曲面人工晶状体视觉差异

日本姬路市崎崎医院眼科的Yamauchi T等人近日在Clin Ophthalmol杂志上发表了一篇文章,他们比较了复曲面人工晶状体(IOL)和由相同材料制成的非复曲面人工晶体在视觉方面的差异。

Clin Exp Optom:圆锥角膜后房型有晶状体人工晶状体植入术的长期结果

伊朗伊朗医科大学Rassoul Akram医院眼科研究中心的Hashemian SJ近日在Clin Exp Optom发表了一项重要工作,对后房人工晶状体(pIOL)植入的长期安全性、有效性、稳定性和可预测性等进行了研究,来校正与圆锥角膜相关的近视和近视散光。